ABSTRACT
Introduction Arboviruses and malaria are both mosquito-borne diseases, with overlapping symptoms and geographic distribution in tropical settings. However, little information is available on the co-occurrence of arboviruses and malaria in areas highly endemic for malaria in Africa. This study was conducted with the aim to determine the frequency of recent Dengue (DENV), Chikungunya (CHIKV) and Zika (ZIKV) infections and their co-occurrence with malaria in six highly endemic districts for malaria in Mozambique.
Methods Blood samples were collected from febrile outpatients between January 2017 and December 2018 and were then tested for Malaria using RDT. Serum samples from these patients were also tested using commercially available ELISA for the presence of IgM antibodies against CHIKV, ZIKV and DENV, as well as NS1 antigen for DENV. Concurrently, a questionnaire was administered to collect socio-demographic characteristics of patients.
Results Of the 906 participants enrolled, IgM antibodies against CHIKV, DENV and ZIKV were identified in 134 (14.8%), 64 (7.4%) and 83 (9.2%) individuals, respectively. Malaria was diagnosed in 56 (6.2%) participants, of which 16 (28.6%) were also positive for IgM anti CHIKV, 1 (1.8%) for DENV-NS1, 3 (5.4%) for IgM anti-DENV and 10 (17.8%) for IgM anti-ZIKV. There was a trend towards an increase in the frequency of IgM anti CHIKV positive samples, from 7.0% in 2014 to 14.8% in 2018 and IgM anti-ZIKV positive samples increased from 4.9% in 2015 to 9.2% in 2018.
Conclusion This study showed an increased frequency of arbovirus in Mozambique thus far, as well as a frequent occurrence of arbovirus among malaria positive patients. This highlighted the urgency for the establishment of sentinel surveillance sites for arboviruses and the need for an integrated management of febrile illnesses in places where arboviruses and malaria are both prevalent.
AUTHOR SUMMARY Arbovirus and malaria share clinical features, which might make the differential diagnosis of acute febrile illnesses significantly difficult, leading to frequent over diagnosis of malaria and under diagnosis of arbovirus in places where both co-occur. In Mozambique and other sub-Saharan countries, epidemiological data on the burden and temporal trend of arbovirus, as well as on co-occurrence with malaria are Chikungunya virus (CHIKV) and Dengue virus (DENV) and its co-occurrence with malaria among 609 febrile patients in six health centres located in five provinces in Mozambique. Recent CHIKV, DENV and ZIKV infection, as measured by presence of IgM antibodies, were found in 14.8%, 7.4% and 9.2% of participants and among 28.6%, 5.4% and 17.8%, of malaria positive patients. These findings suggest that arboviruses are frequent among malaria and non-malaria febrile patients, reinforcing the need for increased awareness of arbovirus in the management of acute febrile illness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work. However, the authors received financial support from the host institution (Instituto Nacional de Saude) for salaries, sample collection and administrative costs.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was obtained from the Mozambican National Bioethics Committee for Health (Ref. No. 487/CNBS/2017). A written informed consent was obtained from all study participants and from parents or guardians of children under the age of 18. All questionnaires were handled anonymously and confidentially.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
